Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata is a genetic and immune-related hair loss condition that is often associated with other autoimmune diseases and does not typically cause permanent damage to hair follicles.

Lasers might help hair growth in some alopecia cases, but more research is needed to confirm their effectiveness and safety.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

The document concludes that Hidradenitis suppurativa is often underdiagnosed, lacks definitive treatment, and requires better awareness and management strategies.

Temporal triangular alopecia is a non-scarring hair loss in children, often linked to other health conditions.

Increased scalp sweating in frontal fibrosing alopecia may be linked to local skin inflammation.

Alopecia areata greatly affects people's life quality, mental health, and work life.

Chronic cutaneous lupus erythematosus causes scarring, hair loss, and skin discoloration, especially on sun-exposed areas.

Alopecia areata involves complex immune and genetic factors, with potential treatment targets identified, but more research is needed.

Regenerative cellular therapies show promise for treating non-scarring hair loss but need more research.

Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.

Early treatment of Lupus Erythematosus Alopecia can prevent permanent hair loss, and various medications are effective.

Platelet-rich plasma (PRP) is effective in treating various skin conditions and improving hair density, thickness, and patient satisfaction, with lower relapse rates for Alopecia Areata.

Congenital triangular alopecia is a hair loss condition present from birth or early childhood with no effective treatment needed.

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

Alopecia areata is unpredictable, with limited treatment effectiveness, especially in severe cases.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Platelet-rich plasma can increase hair density and may help treat some skin conditions, but it's costly, not FDA-approved, and needs more research.

Gender-affirming therapy can cause skin issues like acne and hair loss in transgender adolescents, and more research is needed on its dermatological effects.

Both platelet-rich plasma and low-level laser therapy effectively treat hair loss with minimal side effects and good cost-benefit ratio.

Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.

Non-scarring alopecia in females affects emotional well-being and requires accurate diagnosis and personalized treatment.

Choosing the right treatment for hair loss is complex and depends on effectiveness, side effects, practicality, and cost.

Filler injections can cause temporary hair loss, but hyaluronidase can help restore hair within a few months.

Injecting a peptide-hyaluronic acid mix improved hair growth in men with hair loss and was safe.

Dermatologists are essential in helping transgender and gender diverse patients with skin and hair issues related to gender affirmation and hormone therapy.

Acne necrotica can be effectively treated with topical cream and antibiotics.

Both DPCP alone and with PRP are effective and safe for treating severe alopecia areata.

Treg cell-based therapies might help treat hair loss from alopecia areata, but more research is needed to confirm safety and effectiveness.

Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.